FAP and cancer: FAP inhibitors (FAPis) have been exploited as small-molecule radioligands designed to specifically target FAP with high binding affinity and are actively being investigated for both positron emission tomography (PET) imaging and potential radioligand therapies across various cancer types [5,13].